Şükran Darcan

Şükran Darcan

Auto-generated profile, based on publicly available information

Şükran Darcan

Department of Pediatric Endocrinology, Faculty of Medicine, Ege University, İzmir, Türkiye

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
AAAysun Ata
Aysun Ata
SÖSamim Özen
Samim Özen
HOHüseyin Onay
Hüseyin Onay
SUSelin Uzun
Selin Uzun
DGDamla Gökşen
Damla Gökşen
ŞDŞükran Darcan
Şükran Darcan

1 June 2016 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
LKLeman Damla Kotan
Leman Damla Kotan
CCCharlton Cooper
Charlton Cooper
ŞDŞükran Darcan
Şükran Darcan
ICIan Michael Carr
Ian Michael Carr
SÖSamim Özen
Samim Özen
ELEtienne Leygue
Etienne Leygue
What initiates the pubertal process in humans and other mammals is still unknown. We hypothesized that gene(s) taking roles in triggering human puberty may be identified by studying a cohort of idiopathic hypogonadotropic hypogonadism (IHH). A cohort of IHH cases was studied based on autozygosity mapping coupled with whole exome sequencing. Our studies revealed three independent families in which IHH/delayed puberty is associated with inactivating SRA1 variants. SRA1 was the first gene to be identified to function through its protein as well as noncoding functional ribonucleic acid products. These products act as co-regulators of nuclear receptors including sex steroid receptors as well as SF-1 and LRH-1, the master regulators of steroidogenesis. Functional studies with a mutant SRA1 construct showed a reduced co-activation of ligand-dependent activity of the estrogen receptor alpha, as assessed by luciferase reporter assay in HeLa cells. Our findings strongly suggest that SRA1 gene function is required for initiation of puberty in humans. Furthermore, SRA1 with its alternative products and functionality may provide a potential explanation for the versatility and complexity of the pubertal process.

28 March 2024 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
YÖY. Özer
Y. Özer
AAAhmet Anık
Ahmet Anık
USUgurcan Sayili
Ugurcan Sayili
UTU. Tercan
U. Tercan
RSR. Deveci Sevim
R. Deveci Sevim
OEOlcay Evliyaoglu
Olcay Evliyaoglu
Purpose: We aimed to determine the frequency of transient congenital hypothyroidism (TCH) in 17 participating centers in Türkiye, evaluate the etiological distribution in permanent congenital hypothyroidism (PCH) cases, and investigate the role of laboratory and clinical findings in predicting TCH. Methods: This retrospective observational multicenter study included patients from 17 pediatric endocrinology centers identified by “National Newborn Screening Program” (NNSP) who were born in 2015 and followed for 6 years. Demographic, clinical, and laboratory information of the cases were compiled through the database http://cedd.saglik-network.org (CEDD-NET). Results: Of the 239 cases initially treated for CH, 128 (53.6%) were determined as transient in whom a trial of levothyroxine (LT4) withdrawal was performed at a median age of 36 (34–38) months. Among the patients with PCH (n = 111), thyroid dysgenesis was diagnosed in 39.6% (n = 44). The predictive factors for TCH were: LT4 dose at the withdrawal of treatment, and initial newborn blood screening (NBS)-TSH level. Based on the receiver operating characteristic (ROC) curve analysis to predict optimal cut-offs for TCH predictors, LT4 dose < 2.0 µg/kg/day at treatment discontinuation was predictive for TCH and was associated with 94.5% specificity and 55.7% sensitivity, with an area under the curve (AUC) of 0.802. The initial NBS-TSH level value < 45 µIU/mL was predictive for TCH with 93.1% specificity and 45.5% sensitivity, with an AUC of 0.641. In patients with eutopic thyroid gland only LT4 dose < 1.1 µg/kg/day at withdrawal time was predictive for TCH with 84.7% sensitivity and 40.4% specificity, with an AUC of 0.750. Conclusion: According to our national follow-up data, the frequency of TCH was 53.6%. We determined the LT4 dose < 2.0 µg/kg/day at discontinuation of treatment and the initial NBS-TSH level < 45 µIU/mL as the best cut-off limits to predict TCH.

5 March 2015 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
SPSukran Poyrazoglu
Sukran Poyrazoglu
TATeoman Akçay
Teoman Akçay
IAIlknur Arslanoglu
Ilknur Arslanoglu
MAMehmet Emre Atabek
Mehmet Emre Atabek
ZAZeynep Atay
Zeynep Atay
FDFeyza F. Darendeliler
Feyza F. Darendeliler
Approaches to diagnosis and treatment of growth hormone deficiency (GHD) in children vary among countries and even among centers in the same country. This survey, aiming to facilitate the process of preparing the new consensus on GHD by the Turkish Pediatric Endocrinology and Diabetes Society, was designed to evaluate the current practices in diagnosis and treatment of GHD in different centers in Turkey. A questionnaire covering relevant items for diagnosis and treatment of GHD was sent out to all pediatric endocrinology centers. Twenty-four centers returned the questionnaire. The most frequently used GH stimulation test was L-dopa, followed by clonidine. Eighteen centers used a GH cut-off value of 10 ng/mL for the diagnosis of GHD; this value was 7 ng/mL in 4 centers and 5 ng/mL in 2 centers. The most frequently used assay was immunochemiluminescence for determination of GH, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 concentrations. Sex steroid priming in both sexes was used by 19 centers. The most frequently used starting dose of recombinant human GH (rhGH) in prepubertal children was 0.025-0.030 mg/kg/day and 0.030-0.035 mg/kg/day in pubertal children. Growth velocity was used in the evaluation for growth response to rhGH therapy in all centers. Anthropometric measurements of patients every 3-6 months, fasting blood glucose, bone age and thyroid panel evaluation were used by all centers at follow-up. Main indications for cessation of therapy were decreased height velocity and advanced bone age. Fourteen centers used combined treatment (rhGH and gonadotropin-releasing analogues) to increase final height. Although conformity was found among centers in Turkey in current practice, it is very important to update guideline statements and to modify, if needed, the approach to GHD over time in accordance with new evidence-based clinical studies.

18 May 2018 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
ÖKÖzlem Korkmaz
Özlem Korkmaz
GDGünay Demir
Günay Demir
HÇHafize Çetin
Hafize Çetin
IMİlkin Mecidov
İlkin Mecidov
YAyasemin atik altinok
yasemin atik altinok
DGDamla Gökşen
Damla Gökşen
Objective: To compare continuous subcutaneous insulin infusion (CSII) therapy with multiple daily insulin (MDI) therapy on metabolic control in children and adolescents with type I diabetes mellitus (T1DM) over the long term. Methods: Fifty-two T1DM patients treated with CSII and monitored for at least one year prior to and at least five years following CSII were included. Thirty-eight age and sex-matched MDI controls with a 5-year follow up were recruited. Results: Mean age of the subjects, duration of diabetes and CSII therapy were 17.0 +/- 4.8 years, 10.7 +/- 2.8 years and 7.7 +/- 1.5 years respectively. Mean hemoglobin A1c (HbA I c) in the year prior to CSII, during the first year of treatment and after 5 years of CSII were 7.3 +/- 1 % (56 mmol/mol), 7.0 +/- 0.7% (53 mmol/mol) and 7.8 +/- 1.3 % (62 mmol/mol) respectively. Initial and 5-year mean HbA1C levels of controls were 7.9 +/- 1.08 % and 8.6 +/- 1.8 %. Mean HbA1c values were significantly lower in those receiving CSII therapy throughout follow-up. Basal and total insulin doses were significantly lower in the CSII group at all times. HbA1c was compared between subjects by age (0-5, 6-11 and 12-18 years) with no significant difference between them. Conclusion: Although CSII mean HbA1c values exceeded accepted good metabolic control limits after 5 years, CSII produces better HbA1c control at all times and in all age groups compared to MDI.

1 June 2019 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
GDGünay Demir
Günay Demir
SÖSamim Özen
Samim Özen
HÇHafize Çetin
Hafize Çetin
ŞDŞükran Darcan
Şükran Darcan
DGDamla Gökşen
Damla Gökşen
The aim of this study was to determine the prevalence of impaired hypoglycemia awareness (IHA) in children and adolescents with type 1 diabetes mellitus using a professional continuous glucose monitoring (CGM) system and to show the effect of structured education on glycemic variability (GV) in children and adolescents with IHA. Forty type 1 diabetic children and adolescents with a diabetes duration of at least five years were eligible for inclusion in this prospective, quantitative study. All subjects were asked about their history of being aware of the symptoms of hypoglycemia using a questionnaire. Professional CGM was conducted in all of the patients for six days. The frequency of IHA detected by comparison of CGM and logbook reports were analyzed. Patients with identified IHA underwent a structured training program. After three months, CGM was re-applied to patients with IHA. The study was completed by 37 diabetic children and adolescents. After the initial CGM, nine patients (24.3%) were found to have had episodes of IHA. Area under the curve (AUC) for hypoglycemia and number of low excursions were; 1.81±0.95 and 8.33±3.60 for the IHA group at the beginning of the study. AUC for hypoglycemia was 0.43±0.47 after three months of structured education the IHA patients (p=0.01). Coefficient of variation which shows primary GV decreased significantly although unstable at the end of education in IHA patients (p=0.03). CGM is a valuable tool to diagnose IHA. IHA, GV and time in range can be improved by education-based intervention.